



Sveriges lantbruksuniversitet
Swedish University of Agricultural Sciences

Faculty of Natural Resources and
Agricultural Sciences
Department of Food Science

Long-chain polyunsaturated fatty acid production by microalgae

Långkedjiga fleromättade fettsyror producerade av
mikroalger

Ida Collinius

Long-chain polyunsaturated fatty acid production by microalgae

Långkedjiga fleromättade fettsyror producerade av mikroalger

Ida Collinius

Supervisor: Jana Pickova, Department of Food Science

Examiner: Lena Dimberg, Department of Food Science

Credits: 15 hec

Level: Ground G2E

Course title: Independent Project in Food Science – Bachelor Project

Course code: EX0669

Programme/education: Agricultural Programme - Food Science

Place of publication: Uppsala

Year of publication: 2016

Title of series: Publication / Swedish University of Agricultural Sciences, Department of Food Science

Serie no: 452

Online publication: <http://stud.epsilon.slu.se>

Keywords: Micro algae, LC-PUFA, Eicosanoids

Sveriges lantbruksuniversitet
Swedish University of Agricultural Sciences

Faculty of Natural Resources and Agricultural Sciences
Department of Food Science

Abstract

Long chain polyunsaturated fatty acids (LC-PUFA) are essential to humans and needs to be consumed through the diet instead of production in the body. LC-PUFAs are in this report be categorized into omega-3 and omega-6 fatty acids. The aim of this study was to focus on LC-PUFAs that can be produced by species of microalgae of commercial interests.

There are estimated to exist 200 000 up to millions species of microalgae and the species are as diverse in cultivation strategies as in products. Strains of *Arthrospira* produce γ -linoleic acid (GLA). *Cryptocodinium* species and *Schizochytrium* species produce docosahexaenoic acid (DHA). *Nannochloropsis* species, *Nitzschia* species and *Phaeodactylum* species can be cultivated for the production of eicosa-pentaenoic acid (EPA). *Porphyridium* species are potential for the production of arachidonic acid (AA).

The LC-PUFAs are important due to a wide range of health beneficial services. EPA and AA are the most important producers to eicosanoids among the fatty acids. Eicosanoids are important in the process of cell-signalling and also respond to inflammations. Categories of eicosanoids are prostaglandins, leukotrienes and thromboxane's that are included in blood pressure reductions, pro-inflammatory effects, aggregation of thrombocytes and artery contractions et cetera.

Major depression disease and Alzheimer disease are suggested to benefit from supplements of LC-PUFA. EPA and DHA are part of membranes in the brain, and can improve cognitive functions, hence, have preventative effects to Alzheimer and major depression disease. Cardiovascular disease may also be prevented if sufficient omega-3 fatty acids are consumed. Eicosanoids derived from LC-PUFA may also affect the inflammatory response in the body. Eicosanoids derived from AA have a more severe inflammatory response, while eicosanoids derived from EPA and DHA can have anti-inflammatory response.

Keywords: Micro algae, LC-PUFA, Eicosanoids

Sammanfattning

Långkedjiga fleromättade fettsyror (LC-PUFA) är essentiella för människan vilket innebär att de måste förtäras via dieten eftersom en produktion i kroppen inte är möjlig. LC-PUFA kan i den här rapporten kategoriseras in i 2 huvudgrupper; omega-3 och omega-6. Syftet med denna litteraturstudie var att fokusera på LC-PUFA som kan produceras av olika arter av kommersiellt intressanta mikroalger.

Det beräknas att existera 200 000 till miljontals arter av mikroalger i världen. Arterna är lika mångfaldiga i sin artskildhet som i odlingsstrategi och i sammansättning. Stammar av *Arthrospira* producerar γ -linolensyra (GLA). Arter av *Cryptocodinium* och *Schizochytrium* är potentiella för odling av dokosahexansyra (DHA). Arter av *Nannochloropsis*, *Nitzschia* och *Phaeodactylum* är potentiella för odling av produktion av Eikosapentaensyra (EPA). Arter av *Porphyridium* kan potentiellt odlas för produktion av arakidonsyra (AA).

LC-PUFA konsumtion är viktig på grund av sina utbredda hälsoförtjänster. EPA och AA är de viktigaste producenterna bland fettsyror till en rad olika eikosanoider. Eikosanoider är viktiga i processer så som cellsignalering och ger gensvar på inflammation. Det finns olika kategorier av eikosanoider så som prostaglandiner, leukotriener och tromboxaner. Dessa ingår i funktioner som blodtryckssänkning, trombocyttaggregering, kärlsammandragningar et cetera.

LC-PUFA kan påverka, enligt studier, hälsan hos sjuka individer. Depressions-sjukdomar och Alzheimers har studier föreslagit att motverkas på grund av intag av LC-PUFA. EPA och DHA utgör delar av fosfolipider och membran i hjärnan samt kan förbättra kognitiva funktioner. Hjärt- och kärlsjukdomar kan också förebyggas om omega-3 fettsyror konsumeras, enligt studier. Eikosanoider ursprungligen från LC-PUFA kan även påverka den infammatoriska responsen i kroppen. Eikosanoider från AA har en rikligare inflammatorisk respons medan eikosanoider från EPA och DHA kan ha antiinflammatorisk respons.

Nyckelord: Mikroalger, LC-PUFA, Eikosanoider

Table of content

Abbreviations	5
1 Introduction	6
2 Method	9
1 Long chained polyunsaturated fatty acids	10
1.1 Arachidonic acid	11
1.2 γ -Linolenic acid	11
1.3 Eicosapentaenoic acid	12
1.4 Docosahexaenoic acid	12
2 Health effects from LC-PUFA	13
2.1 Alzheimer disease	13
2.2 Cardiovascular disease	14
2.3 Inflammation	14
2.4 Major depression disease	15
3 Microalgae species and LC-PUFA	16
3.1 <i>Arthrospira</i> species	17
3.2 <i>Cryptocodinium</i> species	17
3.3 <i>Nannochloropsis</i> species	18
3.4 <i>Nitzschia</i> species	18
3.5 <i>Phaeodactylum</i> species	18
3.6 <i>Porphyridium</i> species	19
3.7 <i>Schizochytrium</i> species	19
4 Discussion	21
References	23
Appendix	26

Abbreviations

AA Arachidonic acid
ALA α -Linolenic acid
COX Cyclooxygenase
D-GLA Dihomo γ -linoleic acid
DHA Docosahexaenoic acid
EPA Eicosapentaenoic acid
GLA γ -Linolenic acid
LA Linoleic acid
LC-PUFA Long chain polyunsaturated fatty acid
PUFA Polyunsaturated fatty acid

1 Introduction

Algae are organisms that include a wide range of species that perform approximately 50% of the photosynthesis on the globe (John, 1994). Algae may be macroalgae or microalgae which in both categories includes diversities. Microalgae, also called microphytes, are in focus in this report. In contrast to macroalgae are microalgae smaller (Olaizola, 2003).

The concept of microalgae is wide, and contain all organisms that are small enough (a few μm), unicellular and can mostly live in environments with water. The organism may also be photosynthetic and can be eukaryotic or prokaryotic. This gives opportunities to a wide range of commercial applications such as human nutrition, cosmetics and aquaculture and all are not yet explored (Olaizola, 2003).

The number of species of microalgae that exist are unknown, though estimated to between 200 000 up to millions, while higher plants are estimated to be about 250 000 species (Pulz & Gross, 2004).

Diatoms are a category of microalgae of great importance that fixate about 20 % of the carbon on the planet (Kroth *et al.*, 2008). Blue-green microalgae or cyanobacteria are a category which microalgae show many similarities with, though cyanobacteria are bacteria not algae (SMHI, 2010) and have been categorized as plants due to the photosynthetic properties, but are now called bacteria due to that no defined nucleus exist (Ziboh, 2001).

Microalgae are at the lowest level in the food chain and a source to long chain fatty acids. This give rise to a diversity of wild life in the oceans (Posten & Walter, 2013). All species of microalgae are not suitable for human consumption. Some species have multiple ecosystem favours while some species constitute a risk through algae blooming. Thereby, the algae may toxify the surroundings for fish and wildlife. Humans that consume toxified shellfish or fish may be poisoned (SMHI, 2011).

A few species of microalgae have been used as food supplement and as enrichment in feed for centuries. Accustomed examples are *Nostoc* species in Asia and *Spirulina* (*Arthrospira* species) in Mexico and Africa (Olaizola, 2003).

In comparison to how many species of algae that exists, only a few species are used since a production needs to be in a large scale, the metabolite of interest needs to be found and purified and the process needs to be financially sustainable (Olaizola, 2003).

Arthrospira species, *Chlorella* species, *Dunaliella* species, and *Aphanizomenon* species are the four strains that are dominating the commercial industry of microalgae as human nutrition. The microalgae act as supplements and natural food colorants. Since there are such a wide range of species among microalgae, their biofunction and products are equally different. Due to studies *Arthrospira* species produce primarily long chain polyunsaturated fatty acids (LC-PUFA), *Dunaliella* species produce primarily β -carotene, *Chlorella* species produce primarily chlorophyll and *Aphanizomenon* species promote a good health in general (Spolaore *et al.*, 2006).

According to the variance in biodiversity, bioavailability and products from the species of microalgae, their applications are also different. Microalgae are used for aquaculture, biofuels, cosmetics, human nutrition, supplements et cetera (Olaizola, 2003).

Apart from the four major genus, other important microalgae used for commercial applications are *Chaetoceros* species that are used for aquaculture and indirect consumption. *Cryptocodium* species and *Schizochytrium* species are used for docosahexaenoic acid-oils (DHA-oils) and *Nannochloropsis* species are used for aquaculture feed (Spolaore *et al.*, 2006).

Since the 1930's it has been known that fat is necessary for a good health. Linoleic acid (LA, 18:3, n-6) and α -linolenic acid (ALA, 18:3, n-3) were supplemented to e.g. cure people diseased with different dermatological problems et cetera (Abrahamsson *et al.*, 2013).

The human body cannot synthesize fatty acids (FA) with double bounds on carbon 3 and 6. In different studies, different names rise to longer more unsaturated fatty acids such as; long chained polyunsaturated fatty acids (LC-PUFA), essential fatty acids (EFA) and polyunsaturated fatty acids (PUFA) (Wiktorowska-Owczarek *et al.*, 2015).

LC-PUFAs are essential since the body cannot synthesize them. Two important categories of LC-PUFA are omega-3 and omega-6 FA. Omega-3 FA can be consumed in the diet in the form of ALA and can then be transform to longer omega-3 fatty acids such as docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) in the body. Omega-6 FA can be consumed in the diet in the form of LA that can be transformed into the omega-6 fatty acids γ -linolenic acid (GLA) and

arachidonic acid (AA). The importance of these LC-PUFAs are their beneficial health effects (Livsmedelsverket, 2015b).

Algae are a source to LC-PUFAs, either through purification of the algae into oils, such as DHA-oil, through enrichment of food with dried biomass or through use in aquaculture (Spolaore *et al.*, 2006). Potential ways to use algae for LC-PUFA production are also the use of algae genes, inserted in other crops (Kris-Etherton & Hill, 2008).

The aim of this literature analysis was to describe 7 genuses of microalgae that are used or potentially can be used in the market of human nutrition for their production of LC-PUFA (Harwood & Guschina, 2009). The aim was to answer questions concerning if the conditions of cultivation of microalgae can affect the nutritional value of LC-PUFA and if microalgae is a possible source in comparison with other sources. The functions that the LC-PUFA provide for the human body will also be elucidated.

2 Method

Databases such as Web of Science, Scopus, Primo, PubMed and Google Scholar were used in the literature analysis. In first hand, scientific journals and review articles were studied which referred to more profound scientific publications. The scientific publications were chosen by reading the abstract and then those of interest were read more thoroughly. Many sources were dated and therefore as updated sources as possible were used primarily, though some dated books were used for background facts. Books were searched through the database Primo and were viewed and studied online.

The databases from National Food Agency of Sweden (Livsmedelsverket) were used and also the Swedish Meteorology Authority's website (SMHI).

1 Long chained polyunsaturated fatty acids

In this report the focus is on long chain polyunsaturated fatty acids (LC-PUFA) as a product of 7 genres of microalgae that are cultivated, or has potential to be cultivated for this purpose (Harwood & Guschina, 2009). Arachidonic acid (AA, 20:4 n-6, 9, 12), γ -linolenic acid (GLA, 18:3 n-6, 9, 12), eicosapentaenoic acid (EPA, 20:5 n-3 6, 9, 12, 15) and docosahexaenoic acid (DHA, 22:6 n-3 6, 9, 12, 15,18) are LC-PUFAs that could be connected as a product of the different algae species selected (Spolaore *et al.*, 2006). The chemical structure of the essential LC-PUFAs can be seen in Table 1 (Appendix).

The omega 3 and omega 6 fatty acids are essential for humans, since the human body cannot create double bounds on carbon 3 and 6 in the fatty acid chains (Wiktorowska-Owczarek *et al.*, 2015). This is due to lack of the enzymes Δ 12- and Δ 15-desaturase which inserts the double bounds on the n-3 and n-6 positions. Therefore, these fatty acids need to be consumed through the diet (Abrahamsson *et al.*, 2013).

Linoleic acid (LA, cis-9,12-octadecenoic acid) is the original omega-6 fatty acid that can be consumed in different food such as; maize-oil, sunflower-oil, rapeseed-oil, sesame-oil. AA and GLA are also omega-6 fatty acids, deriving from LA, that can be developed with help from desaturases and elongases (Livsmedelsverket, 2015b). Desaturases are enzymes that are necessary to form double bounds and different elongases are needed to create longer fatty acid chains (Wiktorowska-Owczarek *et al.*, 2015).

α -Linolenic acid (ALA, cis-9,12-octadecatrienoic acid) is the original omega-3 fatty acid that can be consumed in different food such as walnuts, rapeseed-oil, fatty fish and algae. DHA and EPA can be developed from ALA, hence includes to be omega-3 fatty acids. There are also other omega-6 and omega-3 fatty acids whilst AA is the most occurring in the omega-6 family and DHA and EPA are the most occurring in the omega-3 family (Livsmedelsverket, 2015b). The metabolism of the LC-PUFAs in the human body can be seen in Table 2 (Appendix).

Challenges concerning dietary intake of omega-3 and omega-6 fatty acids are that they compete over the same enzymes in the elongation and desaturation process (Gebauer *et al.*, 2006). Therefore, LC omega-6 FA is more easily produced in the body, since it is more abundant in the diet (Gebauer *et al.*, 2006). Though, omega-3 fatty acids have higher affinity to the enzymes (Abrahamsson *et al.*, 2013). Omega-9 fatty acids are also included in this competition (Kinsella *et al.*, 1990).

1.1 Arachidonic acid

AA has an important role to play in the human body to create cell membranes to integrate the cells and also to produce prostaglandins. The concentration of AA in the body tissue is correlated to the dietary intake of LA up to 3 E%. This is the point when the phospholipid membranes in the body are saturated with AA.

There are different ways AA can affect the human body. Lipase enzymes are necessary to decompose AA from the phospholipid membranes. To create the prostaglandins D, E and F, the cyclooxygenase (COX) enzymes are necessary. In the cardiovascular tissue an unstable prostaglandin I₂ (PGI₂) can form by COX and in the thrombocytes, thromboxane A₂ (TXA₂) can form. Another pathway for AA is with lipoxygenase enzymes that converts AA to hydroxyl fatty acids, leukotrienes and lipoxins (Abrahamsson *et al.*, 2013).

AA is the most common occurring long chain fatty acid and owns the competition of lineolate enzymes over EPA and DHA. It is important for humans to consume both omega-6 and omega-3 fatty acids since it is necessary for a normal health (Livsmedelsverket, 2015b). Studies show that an elevation of plasma level of AA is not often desirable. The accumulation of thromboxane's and platelet aggregating peroxidases can have pro-inflammatory effects (Barham *et al.*, 2000).

1.2 γ -Linolenic acid

GLA is an omega-6 fatty acid that is the first product that is produced in the body from the dietary intake of LA (Livsmedelsverket, 2015b), commonly from vegetable oils. GLA is necessary for the omega-6 metabolism and is created in the first desaturation step with Δ 6-desaturase. GLA is then quickly transformed into dihomo- γ -linolenic acid (D-GLA) by a polyunsaturated fatty acid-elongase. D-GLA can be transformed further into AA by Δ 5-desaturase. The desaturase enzymes are membrane bound and needs aerobic conditions (Ziboh, 2001).

In the body GLA creates D-GLA that together with AA and EPA is the primary sources to eicosanoids in the body (Sergeant *et al.*, 2016).

A wide range of diseases, such as i.e. cancer and diabetes, have negative impact on the development from LA into GLA. Inhibited initial pathway to omega-6 fatty acids can be solved through supplements of GLA. By passing the first $\Delta 6$ -desaturaton step, LC-PUFA may be created and instead have beneficial health effects on the diseased. This has been applied in many medicinal purposes (Ziboh, 2001). Even though, supplements of GLA are in some aspects discussed due to that the GLA that is not transformed to D-GLA, can accumulate the plasma levels of AA. High plasma levels of AA can in turn have pro-inflammatory properties (Barham *et al.*, 2000). Besides, D-GLA do not create any prostaglandin or thromboxane of importance (Abrahamsson *et al.*, 2013).

1.3 Eicosapentaenoic acid

EPA is an omega-3 fatty acid that can be transformed in the body from ALA in the diet. ALA is often rich in fish, shellfish, rapeseed et cetera (Livsmedelsverket, 2015b).

EPA has important health influencing effects on humans. EPA is an important source to eicosanoids in the body together with AA and D-GLA and can synthesize the prostaglandin PGI_3 , that is similar to PGI_2 , that has cardio vessel dilating effects (Abrahamsson *et al.*, 2013).

Since omega-6 FA is more abundant in the diet of the western society than omega-3 fatty acids, approximately in 10:1 ratio, this may lead to that AA is more abundant in membranes and tissues of the human body (Parker *et al.*, 2006). Omega-3 fatty acids have a higher affinity to the elongating enzymes in the body and can inhibit the synthesis of AA, and be more abundant in the body (Abrahamsson *et al.*, 2013).

EPA produce the prostaglandin PGI_3 that has similar effects as PGI_2 from AA, while thromboxane from EPA has no crucial effect (Abrahamsson *et al.*, 2013).

1.4 Docosahexaenoic acid

DHA is an omega-3 fatty acid that can be transformed in a minor amount in the body from ALA, which is widespread in the diet. Fish and algae are good sources to DHA and can be consumed directly (Livsmedelsverket, 2015b). Studies claim that the transformation from dietary ALA is insufficient and only occurs into DHA and EPA in 10-15% (Parker *et al.*, 2006). A series of elongation and desaturation steps needs to occur to produce DHA in the human body from ALA (Sergeant *et al.*, 2016).

2 Health effects from LC-PUFA

LC-PUFA create health effects in the human body that may prevent, slow down or improve health (Abrahamsson *et al.*, 2013). Different studies point out that Alzheimer disease, cardiovascular disease, inflammation and major depression disease may have beneficial health aspects from the dietary intake from LC-PUFA (Song *et al.*, 2016; Mori & Beilin, 2004; Kris-Etherton *et al.*, 2003).

Beneficial health effects are due to eicosanoids, derived from fatty acids with 20 carbon atoms, that can control cell signalling and respond to inflammations (Abrahamsson *et al.*, 2013).

Studies have shown that beneficial health effects such as anti-inflammatory response are due to D-GLA (Sergeant *et al.*, 2016). DHA is crucial for a normal brain activity, the nervous system and the cardiovascular system. This is especially during development for a growing and maturing child (Abrahamsson *et al.*, 2013).

2.1 Alzheimer disease

The human brain contains high levels of PUFA. Due to this facts, studies have been performed concerning brain health and its correlation to PUFAs, such as EPA and DHA (Logan, 2003).

Alzheimer disease is a brain disease which has no cure and only have a few options for treatment (Swanson *et al.*, 2012). LC-PUFA may be preventative factors since the brain benefit from their functions. EPA and DHA have important functions in membranes, inflect the neuroimmune and apoptotic pathways and also compete over enzymes with omega-6 fatty acids that may have pro-inflammatory effects (Song *et al.*, 2016).

Studies have shown that neurological functions have improved in correlation with a high intake of DHA in proportion to EPA and that patients with a mild form of Alzheimer might benefit from supplements of DHA and EPA through e.g. improved cognitive functions (Swanson *et al.*, 2012).

2.2 Cardiovascular disease

Studies have shown that people with cardiovascular disease (CVD) can have beneficial health effects from supplements or food rich in omega-3 fatty acids, such as fish.

Intervention studies imply that high blood pressure can be partially reduced, and that high fat compared to low fat and enhanced LA have blood pressure reducing effect. Blood coagulation, aggregation of thrombocytes and extended bleeding time are functions dependent on DHA and EPA (Abrahamsson *et al.*, 2013).

Three epidemiological prospective studies showed that grown men that had an intake of fish more than once a week had decreased risk for coronary heart diseases (Kris-Etherton *et al.*, 2003). The aspect to how women respond to the dietary intake of fish has been concluded to lower risk for coronary heart disease, according to “The Nurses’ health study”, (Hu *et al.*, 2002) performed over 16 years. Though, a number of prospective cohort studies on women showed that atherosclerosis could benefit from the dietary intake of fish, which was contradictory to the studies done in men (Hu *et al.*, 2002).

2.3 Inflammation

Eicosanoids from omega-6 fatty acids are suggested to create inflammation if high dietary intake occur. Eicosanoids derived from AA are proposed as even more severe in the inflammatory response which can be modulated by EPA and DHA derived eicosanoids (Abrahamsson *et al.*, 2013).

In the aspect of anti-inflammatory response, the EPA and DHA omega-3 fatty acids from marine-oil are effective (Mori & Beilin, 2004).

Cytokine production and development of lymphocytes and reactive oxygen radicals are all pro-inflammatory markers, that can be inhibited by eicosanoids derived from EPA and DHA. Therefore, immunological diseases, psoriasis, hypersensitivity, lymphocytes, rheumatism and intestinal diseases have been suggested to be prevented from EPA and DHA (Abrahamsson *et al.*, 2013).

The anti-inflammatory effects deriving from EPA and DHA are shown in trials, preventing atherosclerosis, sudden death, myocardial infarction et cetera (Mori & Beilin, 2004). Studies show that high dietary intake of trans fatty acids and saturated fatty acids in comparison to alpha linolenic acid give rise to pro-inflammatory markers. Exceeding 10 E% of PUFA can give rise to peroxides in the body which can be reduced by vitamin E in the diet (Abrahamsson *et al.*, 2013).

2.4 Major depression disease

Major depression disease (MDD) is a common illness of the brain. Approximately 10% of the population in the world is affected and gets depressive, downhearted, unmotivated, indifferent and apathetic (Song *et al.*, 2016).

Studies have shown that the lipid levels in the bloodstream are less dense in people with MDD or similar diseases, and more abundant in healthy people. Research emphasize the importance of LC-PUFA to the central nervous systems which can be preventative to various of neuropsychiatric disorders (Logan, 2003).

Other studies show connection between MDD and stress, which give rise to dysfunctional hormone levels in the brain and results in low amount of neurotransmitters such as dopamine, serotonin and noradrenaline (Song *et al.*, 2016). Other studies show that post-traumatic stress from pregnancies can have beneficial effects, if treated with LC-PUFA (De Vriese *et al.*, 2003).

3 Microalgae species and LC-PUFA

The microalgae species that are in focus in this report are *Arthrospira* species, *Cryptocodium* species, *Nannochloropsis* species, *Nitzschia* species, *Phaeodactylum* species, *Porphyridium* species and *Schizochytrium* species. These species were chosen in this report due to their production of LC-PUFA; AA, GLA, EPA and DHA (Harwood & Guschina, 2009). The microalgae are used in products in the market or are potential industrial products. (Posten & Walter, 2013).

Strategies to increase LC-PUFA content in microalgae are well studied. Examples of strategies are the possibility of optimization of temperature. The light intensity can be altered, as well as nutrients, the concentration of carbon dioxide, the pH and the salt concentration. There are also more factors that can be included to demonstrate that there are many different ways to alter the composition of the microalgae (Cavonius, 2016). The fatty acid content of the microalgae genres seen in Table 1. in Appendix is modified by a study and describes the content of DHA and EPA in percent of the dried biomass and the yield DHA and EPA in milligram per litre of the total batch cultivation.

Studies results in different values of the total lipid content of microalgae genres. In a study the lipid composition of different microalgae genres was determined by thin-layer chromatography-flame ionization detection. The lipid classes the microalgae species contained were hydrocarbons, triacylglycerols, free fatty acids, sterols and polar lipids (Volkman *et al.*, 1989).

Microalgae yield more oil than conventional crops due to that microalgae use the vegetable oil as storage product, and contain about 50-60% lipids per dry weight of the total biomass (Griffiths & Harrison, 2009). Approximated value of LC-PUFA of the total lipids in percent is given in Table 2. in Appendix.

3.1 *Arthrospira* species

Arthrospira species are blue-green microalgae, which in the market for human consumption are also called *Spirulina*. *Spirulina* is categorized to be a microalgae, but are really spiral shaped dietary consumable cyanobacteria (Vonshak, 1997).

Arthrospira species have long been studied for its fatty acid composition (Muhling *et al.*, 2005). Food supplement oils from *Arthrospira* species can provide rich amounts of GLA. The total lipid content is in general 6-7% of the dried biomass of *Spirulina maxima* (Spolaore *et al.*, 2006).

Due to one study on *S. plantensis* the content of PUFA was 18.6%, monounsaturated fatty acids (MUFA) 1.9% and saturated fatty acids (SFA) 70.3% of the total lipid content. GLA was the major fatty acid of the PUFA (18.5%) followed by LA (13.8%). Also existing were palmitic acid, palmitoleic acid and oleic acid (Yasar & Sevket, 2006).

Arthrospira species are suitable for cultivating for human consumption since they are rather large in comparison with most microalgae, rich in protein and easily can be digested. The production of GLA can be altered by growth conditions such as light intensity, growth phase and temperature. Studies show that the growth condition in 30-35 °C for most strains of *Arthrospira* is richest in GLA. High light intensity and temperature reduces fatty acid content but not composition (Cohen *et al.*, 1987). *Arthrospira* species have been suggested to have an optimized growth under light and dark cycles in laboratory environment or outdoors (Tanticharoen *et al.*, 1994).

3.2 *Cryptocodinium* species

Cryptocodinium cohnii is a heterotrophic microalga that is grown for food and pharmaceutical interests for the production of DHA-oil. Studies has been made on growth conditions to optimize the production of DHA-oil. One study used batch cultivation with sea salt, yeast extract and glucose and compared with another batch with acetic acid as carbon source. The batch with acetic acid showed high biomass, DHA and lipid concentrations (De Swaaf *et al.*, 2003).

Cryptocodinium species are studied to produce DHA (Spolaore *et al.*, 2006). A recent study determined the DHA and EPA proportion of the dried biomass of *Cryptocodinium cohnii*. The results showed that it contained 0.8-1.3% DHA and 0% EPA of the dried biomass and measured in milligram fatty acids per litre of batch culture, DHA reached 15-20 mg/L and EPA 0 mg/L (Cavonius, 2016). Hence, that *Cryptocodinium cohnii* almost exclusively produces DHA makes it a good microorganism for purification process of lipids (Mendes *et al.*, 2009).

3.3 *Nannochloropsis* species

Nannochloropsis species are green microalgae that are cultivated for their chlorophyll, carbohydrate, protein and fatty acid content and some *Nannochloropsis* species also produce LC-PUFA (Volkman *et al.*, 1989). Some species of *Nannochloropsis*, have been shown to produce EPA (Spolaore *et al.*, 2006). In a study, *Nannochloropsis* species grown under enriched CO₂ phototrophic culture conditions gave a higher yield of EPA compared to acetate enriched mix trophic conditions (Hu & Gao, 2003).

Nannochloropsis occulta is composed of 17.8-39.9% EPA of the total fatty acid content (Renaud *et al.*, 1991). A recent study determined the DHA and EPA proportion of the dried biomass of *Nannochloropsis* species. The results showed that it contained 0-0.7% DHA and 0-8.2% EPA and contained 0-2.6 mg/L DHA and 0-14 mg/L EPA in the total batch culture (Cavonius, 2016).

3.4 *Nitzschia* species

Nitzschia laevis is a diatom (Chen *et al.*, 2007), which means that the microalga contain silicon in the cell wall (SMHI, 2011).

Nitzschia species have been confirmed to produce EPA (Spolaore *et al.*, 2006). In a study *Nitzschia laevis* showed that the EPA production was most sufficient in a mix trophic growth culture compared to using single trophic conditions (Wen & Chen, 2000). *Nitzschia laevis* is a potential for production of EPA and the distribution of EPA has been shown to be spread among the classes of lipids. In one study regarding *Nitzschia laevis*, the total lipid content constituted 78.6% neutral lipids. Out of these neutral lipids, 87.9% was triacylglycerols and out of the triacylglycerols, 75.9% was EPA (Chen *et al.*, 2007).

A recent study determined the DHA and EPA proportion of the dried biomass of *Nitzschia* species. The results showed that it contained no detected DHA and 1.1-1.5% EPA and the total batch culture contained no detected DHA/EPA in mg/L (Cavonius, 2016).

3.5 *Phaeodactylum* species

Phaeodactylum tricornutum are diatoms that are potentially used for the production of EPA-oil for omega-3 supplement. *Phaeodactylum* species have been confirmed to produce EPA (Spolaore *et al.*, 2006). A study showed that the cultivation of *Phaeodactylum tricornutum* have higher production of EPA and PUFA at slightly lower temperatures than at higher temperatures (Jiang & Gao, 2004).

In another study of the fatty acid composition, it was found that the EPA content was high in the strains studied. The highest amount of EPA was 25.65% of the

total lipids (Wu *et al.*, 2016). A recent study determined the DHA and EPA proportion of the dried biomass of *Phaedactylum tricornerutum*. The results were 0-0.4% DHA and 0.2-5.5% EPA and the total batch culture contained 0-11 mg/L DHA and 1.3-130 mg/L EPA (Cavonius, 2016).

3.6 *Porphyridium* species

Porphyridium species are red marine microalgae that produce the LC-PUFAs AA and EPA. AA is of special interest since it is unusual to be produced (Cohen *et al.*, 1988). A study showed that slow growth conditions and nitrogen starvation on *Porphyridium cruentum* resulted in the highest values 2.9% AA in ash free dry weight and 2.4% EPA of total lipids in ash free dry weight (Cohen, 1990). Microalgae are produced for DHA-oils and EPA-oils as food supplements (Spolaore *et al.*, 2006). The *Porphyridium* species produce AA and have potential to be directly consumed (Spolaore *et al.*, 2006).

To be able to yield the production of AA by *Porphyridium* species it is suggested that the light intensity should be 8000 lux and the temperature 32°C in liquid cultures of 12×10^9 cells/L (Ahern *et al.*, 1983). A recent study determined the DHA and EPA proportion of the dried biomass of *Porphyridium* species. The results were 0% DHA and <0.1-3.8% EPA and the total batch culture contained 0 mg/L DHA and <1-69 mg/L EPA (Cavonius, 2016).

3.7 *Schizochytrium* species

Schizochytrium species are thraustochytrids, which means algae-like fungi (Ziboh, 2001). *Schizochytrium* species are marine microheterotrophic organisms, which has been detected to produce high biomass containing LC-PUFA. Though, these LC-PUFA profiles are rather complex and that yields production costs. Thraustochytrids with simpler LC-PUFA profiles are preferable in a production point of view (Lewis *et al.*, 1999).

Schizochytrium species produce DHA (Spolaore *et al.*, 2006). The *Schizochytrium* species strain 31 can improve production of DHA when the cultures are incubated during 4 days with initial of pH 7.0, with 0.4% (w/v) yeast extract and with 20 g/L glucose (Wu *et al.*, 2005).

Schizochytrium mangrovei isolated from decaying mangrove forest in Hong Kong was studied for fatty acid content and DHA was found to be the most abundant fatty acid. The percentage DHA was 32.29-39.14% of the total fatty acid content (Jiang *et al.*, 2004). A recent study determined the DHA and EPA proportion out of the dried biomass of *Schizochytrium aggregatum*. The results were 0-

0.3% DHA and 1.0-1.2% EPA and the total batch culture contained 0-<1 mg/L DHA and 6.1-9.3 mg/L EPA (Cavonius, 2016).

4 Discussion

Many studies have shown that the composition of microalgae can be altered due to different culture conditions. Different strains in each species prefer different conditions and some strains produce more LC-PUFA than others (Wu *et al.*, 2005; Hu & Gao, 2003; Jiang *et al.*, 1999; Renaud *et al.*, 1991).

Fish oil is used as the main source for supplements of EPA and DHA, and studies show this to be successful (Parker *et al.*, 2006; Kris-Etherton *et al.*, 2003).

Fish industries have concerns regarding sustainability though microalgae may be an alternative. Microalgae are also superior to crops that accumulate omega-3 FA, in the aspect of cultivation space, maturation time and higher growth rate (Mercer & Armenta, 2011).

Studies have shown that fish accumulate toxins and pollutants which have given an increased interest in microalgae as supplements in replacement (Mimouni *et al.*, 2015). Pregnant women that are especially sensitive for the safety for their fetus are recommended to limit their dietary intake of some fish (Livsmedelsverket, 2015a).

A downside to microalgae cultivation is the use of water. The large amount of water in the algae culture requires cheap energy methods to dry the biomass (Cavonius, 2016).

The separation methods that are used to release lipids into organic solvents from microalgae are not environmentally sustainable. Methods, to be able to use microalgae as an environmental alternative to gain LC-PUFA is under research and one study shows that it is possible to take advantage of the solvent characteristics and use pH shifting to extract soluble material (Cavonius, 2016).

Some algae might be better than others depending on what kind of LC-PUFA that is of interest. Though, the quota of EPA and DHA that is most beneficial is not possible to determine. The total amount of dietary intake of EPA and DHA is more important for a good health (Livsmedelsverket, 2015b). Microalgae supplement may be a good source to LC-PUFA as long as common food is not neglected

(Livsmedelsverket, 2015c). Fish is a good source within reasonable ranges (Livsmedelsverket, 2015a).

Microalgae are a good source to LC-PUFAs if cultivated in financially sustainable systems. Microalgae are only discussed superficially due to the existing thousands of species. Microalgae need less cultivation space than plants and fishery ponds and produce high biomass. Microalgae yield about 50-60% dry weight lipids of the total biomass which is more oil production than conventional crops due to that microalgae use the vegetable oil as storage product.

In comparison with how many species of algae that exists, only a few species are used since a production needs to be in large scale and the metabolite of interest needs to be found and purified to be financially sustainable.

LC-PUFA are essential for humans and can in some cases be needed for supplements, especially for target groups. LC-PUFA is needed for the infant's development, pregnant women also need to keep this in mind, hence algal supplement may be suitable. Microalgae (wet mass) do not contain pollutants and toxins in same range as fish products.

The correlation between the dietary intake of omega-3 and omega-6 fatty acids is more important than the actual amount out of each category, while the optimal correlation is not set.

There is need for more controlled clinical trials with more subjects to be able to draw more conclusions considering microalgae. It is crucial to distinguish socio-demographic variables such as gender, age et cetera in the trials. This is due to the fact that LC-PUFA is more important during different stages in the maturation phases and also to different individuals.

References

- Abedi, E. & Sahari, M.A. (2014). Long chain polyunsaturated fatty acid sources and their nutritional and functional properties. *Food science & nutrition*, 2(5), pp. 443-463.
- Abrahamsson, L., Andersson, A. & Nilsson, G. (2013). Näringslära för högskolan: från grundläggande till avancerad nutrition, p. 68.
- Ahern, T.J., Katoh, S. & Sada, E. (1983). Arachidonic-Acid Production by the Red Alga *Porphyridium-Cruentum*. *Biotechnol Bioeng*, 25(4), pp. 1057-1070.
- Barham, J.B., Edens, M.B., Fonteh, A.N., Johnson, M.M., Easter, L. & Chilton, F.H. (2000). Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. *J Nutr*, 130(8), pp. 1925-31.
- Cavonius, L.R. (2016). Fractionation of lipids and proteins from the microalga *Nannochloropsis oculata*, p. 11.
- Chen, G.-Q., Jiang, Y. & Chen, F. (2007). Fatty acid and lipid class composition of the eicosapentaenoic acid-producing microalga, *Nitzschia laevis*. *Food chemistry*, 104(4), pp. 1580-1585.
- Cohen, Z. (1990). The Production Potential of Eicosapentaenoic and Arachidonic Acids by the Red Alga *Porphyridium-Cruentum*. *Journal of the American Oil Chemists Society*, 67(12), pp. 916-920.
- Cohen, Z., Vonshak, A. & Richmond, A. (1987). Fatty-Acid Composition of *Spirulina* Strains Grown under Various Environmental-Conditions. *Phytochemistry*, 26(8), pp. 2255-2258.
- Cohen, Z., Vonshak, A. & Richmond, A. (1988). Effect of Environmental-Conditions on Fatty-Acid Composition of the Red Alga *Porphyridium-Cruentum* - Correlation to Growth-Rate. *Journal of Phycology*, 24(3), pp. 328-332.
- De Swaaf, M.E., Sijtsma, L. & Pronk, J.T. (2003). High-cell-density fed-batch cultivation of the docosahexaenoic acid producing marine alga *Cryptocodinium cohnii*. *Biotechnol Bioeng*, 81(6), pp. 666-72.
- De Vriese, S.R., Christophe, A.B. & Maes, M. (2003). Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. *Life Sci*, 73(25), pp. 3181-7.
- Gebauer, S.K., Psota, T.L., Harris, W.S. & Kris-Etherton, P.M. (2006). n-3 fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits. *Am J Clin Nutr*, 83(6 Suppl), pp. 1526S-1535S.
- Griffiths, M.J. & Harrison, S.T.L. (2009). Lipid productivity as a key characteristic for choosing algal species for biodiesel production. *Journal of applied phycology*, 21(5), pp. 493-507.
- Harrington, G.W. & Holz, G.G., Jr. (1968). The monoenoic and docosahexaenoic fatty acids of a heterotrophic dinoflagellate. *Biochim Biophys Acta*, 164(1), pp. 137-9.
- Harwood, J.L. & Guschina, I.A. (2009). The versatility of algae and their lipid metabolism. *Biochimie*, 91(6), pp. 679-684.
- Hu, F.B., Bronner, L., Willett, W.C., Stampfer, M.J., Rexrode, K.M., Albert, C.M., Hunter, D. & Manson, J.E. (2002). Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. *Jama-Journal of the American Medical Association*, 287(14), pp. 1815-1821.

- Hu, H. & Gao, K. (2003). Optimization of growth and fatty acid composition of a unicellular marine picoplankton, *Nannochloropsis* sp., with enriched carbon sources. *Biotechnology Letters*, 25(5), pp. 421-5.
- Jiang, H. & Gao, K. (2004). Effects of lowering temperature during culture on the production of polyunsaturated fatty acids in the marine diatom *Phaeodactylum tricornutum* (bacillariophyceae) 1. *Journal of Phycology*, 40(4), pp. 651-654.
- Jiang, Y., Chen, F. & Liang, S.Z. (1999). Production potential of docosahexaenoic acid by the heterotrophic marine dinoflagellate *Cryptocodinium cohnii*. *Process Biochemistry*, 34(6-7), pp. 633-637.
- Jiang, Y., Fan, K.W., Wong, R.D.Y. & Chen, F. (2004). Fatty acid composition and squalene content of the marine microalga *Schizochytrium mangrovei*. *Journal of Agricultural and Food Chemistry*, 52(5), pp. 1196-1200.
- John, D. (1994). Biodiversity and conservation: an algal perspective. *The Phycologist*, 38, pp. 3-15.
- Kinsella, J.E., Broughton, K.S. & Whelan, J.W. (1990). Dietary unsaturated fatty acids: interactions and possible needs in relation to eicosanoid synthesis. *J Nutr Biochem*, 1(3), pp. 123-41.
- Kris-Etherton, P.M., Harris, W.S., Appel, L.J. & Comm, N. (2003). Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Arteriosclerosis Thrombosis and Vascular Biology*, 23(2), pp. E20-E31.
- Kris-Etherton, P.M. & Hill, A.M. (2008). N-3 fatty acids: food or supplements? *J Am Diet Assoc*, 108(7), pp. 1125-30.
- Kroth, P.G., Chiovitti, A., Gruber, A., Martin-Jezequel, V., Mock, T., Parker, M.S., Stanley, M.S., Kaplan, A., Caron, L., Weber, T., Maheswari, U., Armbrust, E.V. & Bowler, C. (2008). A model for carbohydrate metabolism in the diatom *Phaeodactylum tricornutum* deduced from comparative whole genome analysis. *PLoS One*, 3(1), p. e1426.
- Lewis, T.E., Nichols, P.D. & McMeekin, T.A. (1999). The Biotechnological Potential of Thraustochytrids. *Mar Biotechnol (NY)*, 1(6), pp. 580-587.
- Livsmedelverket (2015-11-16). *Dioxiner och PCB*. <http://www.livsmedelverket.se/livsmedel-och-innehall/oonskade-amnen/miljogifter/dioxiner-och-pcb/> [2016-05-19].
- Livsmedelverket (2015-10-08). *Fleromättat fett, omega-3, omega-6*. http://www.livsmedelverket.se/livsmedel-och-innehall/naringsamne/fett/fleromattat-fett-omega-3-och-omega-6/? t_id=1B2M2Y8AsgTpgAmY7PhCf%3d%3d& t_q=arakidonsyra& t_tags=language%3asv%2csiteid%3a67f9c486-281d-4765-ba72-ba3914739e3b& t_ip=212.25.155.97& t_hit.id=Livs Common Model PageTypes ArticlePage/ e522077d-e183-4f3a-9fc2-0d6c6c19a772_sv& t_hit.pos=1 [2016-05-19].
- Livsmedelverket (2015-12-02). *Vem behöver kosttillskott?* <http://www.livsmedelverket.se/livsmedel-och-innehall/kosttillskott/vem-behover-kosttillskott/> [2016-05-19].
- Logan, A.C. (2003). Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. *Altern Med Rev*, 8(4), pp. 410-25.
- Mendes, A., Reis, A., Vasconcelos, R., Guerra, P. & da Silva, T.L. (2009). *Cryptocodinium cohnii* with emphasis on DHA production: a review. *Journal of applied phycology*, 21(2), pp. 199-214.
- Mercer, P. & Armenta, R.E. (2011). Developments in oil extraction from microalgae. *European Journal of Lipid Science and Technology*, 113(5), pp. 539-547.
- Mimouni, V., Ulmann, L., Haimeur, A., Guéno, F., Meskini, N. & Tremblin, G. (2015). Marine microalgae used as food supplements and their implication in preventing cardiovascular diseases. *OCL*, 22(4), p. D409.
- Mori, T.A. & Beilin, L.J. (2004). Omega-3 fatty acids and inflammation. *Curr Atheroscler Rep*, 6(6), pp. 461-7.
- Muhling, M., Belay, A. & Whitton, B.A. (2005). Variation in fatty acid composition of *Arthrospira* (*Spirulina*) strains. *Journal of applied phycology*, 17(2), pp. 137-146.
- Olaizola, M. (2003). Commercial development of microalgal biotechnology: from the test tube to the marketplace. *Biomol Eng*, 20(4-6), pp. 459-66.
- Parker, G., Gibson, N.A., Brotchie, H., Heruc, G., Rees, A.M. & Hadzi-Pavlovic, D. (2006). Omega-3 fatty acids and mood disorders. *Am J Psychiatry*, 163(6), pp. 969-78.

- Posten, C. & Walter, C. (2013). *Microalgal biotechnology: integration and economy*: Walter de Gruyter.
- Pulz, O. & Gross, W. (2004). Valuable products from biotechnology of microalgae. *Appl Microbiol Biotechnol*, 65(6), pp. 635-48.
- Renaud, S.M., Parry, D.L., Thinh, L.V., Kuo, C., Padovan, A. & Sammy, N. (1991). Effect of Light-Intensity on the Proximate Biochemical and Fatty-Acid Composition of Isochrysis Sp and Nannochloropsis-Oculata for Use in Tropical Aquaculture. *Journal of applied phycology*, 3(1), pp. 43-53.
- Sergeant, S., Rahbar, E. & Chilton, F.H. (2016). Gamma-linolenic acid, Dihommo-gamma linolenic, Eicosanoids and Inflammatory Processes. *Eur J Pharmacol*.
- SMHI (2014-14-23). *Algblomningar i Östersjön*. <http://www.smhi.se/kunskapsbanken/oceanografi/algblomningar-i-ostersjon-1.3008> [2016-05-19].
- SMHI (2015-07-09). *Alger*. <http://www.smhi.se/kunskapsbanken/oceanografi/alger-1.6025> [2016-05-19].
- Song, C., Shieh, C.H., Wu, Y.S., Kalueff, A., Gaikwad, S. & Su, K.P. (2016). The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer's disease: Acting separately or synergistically? *Prog Lipid Res*, 62, pp. 41-54.
- Spolaore, P., Joannis-Cassan, C., Duran, E. & Isambert, A. (2006). Commercial applications of microalgae. *Journal of Bioscience and Bioengineering*, 101(2), pp. 87-96.
- Swanson, D., Block, R. & Mousa, S.A. (2012). Omega-3 fatty acids EPA and DHA: health benefits throughout life. *Adv Nutr*, 3(1), pp. 1-7.
- Tanticharoen, M., Reungjitchachawali, M., Boonag, B., Vonkaveesuk, P., Vonshak, A. & Cohen, Z. (1994). Optimization of Gamma-Linolenic Acid (Gla) Production in Spirulina-Platensis. *Journal of applied phycology*, 6(3), pp. 295-300.
- Wen, Z.Y. & Chen, F. (2000). Production potential of eicosapentaenoic acid by the diatom Nitzschia laevis. *Biotechnology Letters*, 22(9), pp. 727-733.
- Wiktorowska-Owczarek, A., Berezinska, M. & Nowak, J.Z. (2015). PUFAs: Structures, Metabolism and Functions. *Adv Clin Exp Med*, 24(6), pp. 931-41.
- Volkman, J., Jeffrey, S., Nichols, P., Rogers, G. & Garland, C. (1989). Fatty acid and lipid composition of 10 species of microalgae used in mariculture. *Journal of Experimental Marine Biology and Ecology*, 128(3), pp. 219-240.
- Vonshak, A. (1997). *Spirulina platensis arthrospira: physiology, cell-biology and biotechnology*: CRC Press.
- Wu, H.L., Li, T., Wang, G.H., Dai, S.K., He, H. & Xiang, W.Z. (2016). A comparative analysis of fatty acid composition and fucoxanthin content in six Phaeodactylum tricornutum strains from different origins. *Chinese Journal of Oceanology and Limnology*, 34(2), pp. 391-398.
- Wu, S.T., Yu, S.T. & Lin, L.P. (2005). Effect of culture conditions on docosahexaenoic acid production by Schizochytrium sp S31. *Process Biochemistry*, 40(9), pp. 3103-3108.
- Yasar, D. & Sevket, G. (2006). α -tocopherol and Fatty acids of Spirulina platensis biomass in Glass panel bioreactor. *Pak J Biol Sci*, 9, pp. 2901-2904.
- Ziboh, V.A. (2001). *Gamma Linolenic Acid: Recent advances in biotechnology and clinical applications*: The American Oil Chemists Society.

Appendix




Figure 1. Chemical structures of LC-PUFA, modified from: (Abedi & Sahari, 2014).




Figure 2. Metabolism of essential fatty acids in the human body. ALA= α -linolenic acid, LA= Linoleic acid, D-GLA= Dihomo γ -linoleic acid, AA= Arachidonic acid, EPA= Eicosapentaenoic acid, DHA= Docosahexaenoic acid. Modified by: (Kris-Etherton & Hill, 2008).

Tabell 1. Microalgae used for human nutrition and the production of DHA and EPA of dried biomass in % and the yield of fatty acids of batch cultivation in mg/L. Modified from Cavonius, 2016.

Genuses	DHA (% of dried biomass)	EPA (% of dried biomass)	DHA (mg/L)	EPA (mg/L)
<i>Cryptocodinium cohnii</i>	0.8-1.3	0	15-20	0
<i>Nannochloropsis</i> species	0-0.7	0-8.2	0-2.6	0-14
<i>Nitzschia</i> species	Not detected	1.1-1.5	Not detected	Not detected
<i>Phaeodactylum tricornutum</i>	0-0.4	0.2-5.5	0-11	1.3-130
<i>Porphyridium</i> species	0	<0.1-3.8	0	<1-69
<i>Schizochytrium aggregatum</i>	0-0.3	1.0-1.2	0-<1	6.1-9.3

Tabell 2. Microalgae species used for human nutrition. The approximated value LC-PUFA of the total lipids and other approximated FA values. DHA= docosahexaenoic acid, EPA= eicosapentaenoic acid, MUFA= monounsaturated fatty acids, NL= neutral lipids, SFA= saturated fatty acids, TAG= triacylglycerols ((1) Cavonius, 2016; (2) Wu et al, 2016; (3) Chen et al, 2007; (4) Jiang et al, 2004; (5) Cohen, 1990; (6) Yasar & Sevket, 2006).

Genuses	Approximated value LC-PUFA of total lipids (%)	Other approximated FA values and lipids
<i>Arthrospira</i> species	18.6 (7)	1.9% MUFA, 70,3% SFA of total lipids (6)
<i>Cryptocodinium</i> species	30-50 (1)	0.8-1.3% DHA, 0% EPA of dried biomass (1)
<i>Nannochloropsis</i> species	0-8.2 (1)	0-0.7% DHA, 0-8.2% EPA of dried biomass (1)
<i>Nitzschia</i> species	-	75.9% EPA of 87.9% TAG of 78.6% NL of total lipids (3)
<i>Phaeodactylum</i> species	25.6 (2)	0-0.4% DHA, 0.2-5.5% EPA of dried biomass (1)
<i>Porphyridium</i> species	0- 2.9 (5)	0% DHA, <0.1-3.8% EPA Of dried biomass (1)
<i>Schizochytrium</i> species	32.2-39.1 (4)	0-0.3% DHA, 1.0-1-2% EPA Of dried biomass (1)